Table 4.
Generalized Linear Mixed Model With Zika Virus and Chikungunya Virus Serology Using a Similar Approach as Table 3 (+/+ or −/− Dyads vs +/− or −/+ Dyads)
| Category | Serological Data | Odds Ratio [95% CI] | P Value for Type 3 Effects | Covariance Parameter Estimates (SE) |
|---|---|---|---|---|
| All participants | ZIKV PRNT50 | 1.65 [0.97–2.78] | .06* | 0.33 (0.25) |
| ZIKV IgG | 1.19 [0.62–2.27] | .60 | 0.87 (0.37) | |
| CHIKV IgG | 0.98 [0.58–1.66] | .93 | 0.41 (0.26) | |
| Participants ≥18 yo | ZIKV PRNT50 | 1.72 [0.91–3.24] | .09* | 0.74 (0.40) |
| ZIKV IgG | 1.11 [0.54–2.29] | .78 | 0.72 (0.48) | |
| CHIKV IgG | 0.84 [0.47–1.51] | .55 | 0.28 (0.35) |
Values significantly or marginally different are indicated in bold.
Abbreviations: CI, confidence interval; CHIKV, chikungunya virus; IgG, immunoglobulin G; PRNT50, plaque reduction neutralization test resulting in 50% plaque reduction; SE, standard error; yo, years old; ZIKV, Zika virus.
*Marginally different (P ≤ .1). Calculations were performed using the GLIMMIX procedure.